{"podcast":{"title":"Blood Cancer Talks","slug":"blood-cancer-talks-5570002","podcast_index_feed_id":5570002,"rss_url":"https://feeds.transistor.fm/bloodcancertalks","website_url":null,"image_url":"https://img.transistorcdn.com/W_5G4oA5kAcf9vixuJQw-sMFE98Hvnnp4pex_BzuYvE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.jpg","author":"Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff","episode_count":75,"summary":"This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk","last_synced_at":"2026-09-03T22:19:58.611204+00:00","page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002"},"episode":{"title":"Episode 58: CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN) with Dr. Piers Blombery","slug":"episode-58-car-transgenic-t-cell-lymphoproliferative-neoplasms-cttln-with-dr-piers-blombery","published_at":"2025-03-26T10:22:25+00:00","page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-58-car-transgenic-t-cell-lymphoproliferative-neoplasms-cttln-with-dr-piers-blombery","show_page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002","url":"https://share.transistor.fm/s/9da2f779","audio_url":"https://media.transistor.fm/9da2f779/ac668be8.mp3","summary":"In this episode, we explore the emerging entity of CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN), a rare but important complication of CAR T-cell therapy. Dr. Piers Blombery from Peter MacCallum Cancer Center joins us to dissect two cases from the CARTITUDE-4 trial where patients developed T-cell lymphomas expressing the chimeric antigen receptor following cilta-cel treatment for multiple myeloma. As a bonus, we also briefly discussed Dr. Blombery’s paper on menin inhibitors in UBTF tandem duplicated AML. Here are the papers we discussed: 1. CTTLN cases from CARTITUDE-4: https://pubmed.ncbi.nlm.nih.gov/39938094/ 2. CTTLN case from MSKCC with insertional mutagenesis: https://pubmed.ncbi.nlm.nih.gov/39908432/ 3. Other CTTLN cases in myeloma: https://pubmed.ncbi.nlm.nih.gov/38865661/ https://pmc.ncbi.nlm.nih.gov/articles/PMC8417502/ 4. Response and resistance to menin inhibitors in UBTF tandem duplication AML: https://pubmed.ncbi.nlm.nih.gov/38924737/","meta_description":"In this episode, we explore the emerging entity of CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN), a rare but important complication of CAR T…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3024,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-58-car-transgenic-t-cell-lymphoproliferative-neoplasms-cttln-with-dr-piers-blombery/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-58-car-transgenic-t-cell-lymphoproliferative-neoplasms-cttln-with-dr-piers-blombery.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}